Biofrontera Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BFRI | DERM | 4A5.F | DMP.F | 08HH.F | FBIO | |
|---|---|---|---|---|---|---|
| Market cap | 13.42M | 133.50M | 1.76B | 1.93B | 5.17B | 65.70M |
| P/E (TTM) | — | — | 19.2 | 14.1 | 11.4 | 0.7 |
| Forward P/E | 2.1 | -78.8 | — | 13.1 | — | -1.1 |
| Price/book | 2.2 | 4.1 | 3.0 | 3.6 | 0.8 | 0.4 |
| Dividend yield | — | — | 1.72% | 2.26% | 2.64% | — |
| 1-year change | −18.35% | −47.51% | +16.35% | +18.72% | −24.11% | −21.77% |
| Today | +1.56% | +1.94% | +2.57% | +1.17% | +1.79% | +1.55% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All BFRI news ›Head to Head Review: Royalty Pharma (NASDAQ:RPRX) versus Biofrontera (NASDAQ:BFRI)
Posted by Tristan Rich on Oct 25th, 2026 Biofrontera (NASDAQ:BFRI – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses…
Contrasting Eton Pharmaceuticals (NASDAQ:ETON) and Biofrontera (NASDAQ:BFRI)
Posted by Tristan Rich on Oct 24th, 2026 Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Biofrontera (NASDAQ:BFRI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body
The Dermatology Digest Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body Ameluz PDT is currently FDA approved for AKs on the face and scalp and, since September 2026, for superficial basal cell carcinoma (sBCC
More from 1 other outlet
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
The Phase 3 trial reported complete lesion clearance in 45.6% of Ameluz patients versus 16.7% with vehicle treatment. A randomized, vehicle-controlled Phase 3 trial enrolled 172 patients. Complete clearance of all treated lesions 12 weeks…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.